Association of polymorphisms in iNOS and NQO1 with bladder cancer risk in cigarette smokers

Journal of the Chinese Medical Association

Volumn 77, Issue 2, 2014, Pages 83-88

  Huang, Zhon Min ^a   Chen, Hsin An ^b,c   Chiang, Yi Te ^b   Shen, Cheng Huang ^d,e   Tung, Min Che ^a,c   Juang, Guang Dar ^f,g  

^a TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^e TAINAN UNIVERSITY OF TECHNOLOGY   (Taiwan)

^f SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^g FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

Bladder cancer; Cigarette smoking; INOS; NQO1; Polymorphism

Indexed keywords

GENOMIC DNA; PROTEINASE K;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GENE; GENE FREQUENCY; GENE INTERACTION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INOS GENE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NQO1 GENE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SMOKING; STRUCTURED QUESTIONNAIRE; TAIWAN;

BLADDER CANCER; CIGARETTE SMOKING; INOS; NQO1; POLYMORPHISM;

FEMALE; HUMANS; MALE; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); NITRIC OXIDE SYNTHASE TYPE II; POLYMORPHISM, GENETIC; SMOKING; URINARY BLADDER NEOPLASMS;

EID: 84893003994     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/j.jcma.2013.10.005     Document Type: Article

References (35)

1. Cancer registry annual report 2012, Bureau of Health Promotion, Department of Health, Taiwan, Republic of ChinaDepartment of Health, Taiwan, Republic of China.
2. Wang Y.H., Yeh S.D., Shen K.H., Shen C.H., Juang G.D., Hsu L.I., et al. A significantly joint effect between arsenic and occupational exposures and risk genotypes/diplotypes of CYP2E1, GSTO1 and GSTO2 on risk of urothelial carcinoma. Toxicol Appl Pharmacol 2009, 241:111-118.
3. Colin P., Koenig P., Ouzzane A., Berthon N., Villers A., Biserte J., et al. Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int 2009, 104:1436-1440.
4. Strope S.A., Montie J.E. The causal role of cigarette smoking in bladder cancer initiation and progression, and the role of urologists in smoking cessation. J Urol 2008, 180:31-37.
5. Karagas M.R., Park S., Warren A., Hamilton J., Nelson H.H., Mott L.A., et al. Gender, smoking, glutathione-S-transferase variants and bladder cancer incidence: a population-based study. Cancer Lett 2005, 219:63-69.
6. Vineis P., Talaska G., Malaveille C., Bartsch H., Martone T., Sithisarankul P., et al. DNA adducts in urothelial cells: relationship with biomarkers of exposure to arylamines and polycyclic aromatic hydrocarbons from tobacco smoke. Int J Cancer 1996, 65:314-316.
7. Ross D., Kepa J.K., Winski S.L., Beall H.D., Anwar A., Siegel D. NAD(P)H: quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact 2000, 129:77-97.
8. Siegel D., Gustafson D.L., Dehn D.L., Beall H.D., Anwar A., Siegel D. NAD(P)H: quinone oxidoreductase 1: role as a superoxide scavenger. Mol Pharmacol 2004, 65:1238-1247.
9. Chao C., Zhang Z.F., Berthiller J., BoVetta P., Hashibe M. NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006, 15:979-987.
10. Ding R., Lin S., Chen D. Association of NQO1 rs1800566 polymorphism and the risk of colorectal cancer: a meta-analysis. Int J Colorectal Dis 2012, 27:885-892.
11. Choudry G.A., Stewart P.A., Double J.A., Krul M.R., Navlor B., Flannigan G.M., et al. A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9. Br J Cancer 2001, 85:1137-1146.
12. Shen C.H., Wang Y.H., Wang W.C., Jou Y.C., Hsu H.S., Hsieh H.Y., et al. Inducible nitric oxide synthase promoter polymorphism, cigarette smoking, and urothelial carcinoma risk. Urology 2007, 69:1001-1006.
13. Ryk C., Steineck G., Wiklund N.P., Nyberg T., de Verdier P.J. The (CCTTT)n microsatellite polymorphism in the nitric oxide synthase 2 gene may influence bladder cancer pathogenesis. J Urol 2010, 184:2150-2157.
14. Förstermann U., Closs E.I., Pollock J.S., Nakane M., Schwarz P., Gath I., et al. Isoforms of nitric oxide synthase: properties, cellular distribution and expressional control. Biochem Pharmacol 1995, 50:1321-1332.
15. Fukumura D., Kashiwagi S., Jain R.K. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006, 6:521-534.
16. Hosseini A., Koskela L.R., Ehrén I., Aguilar-Santelises M., Sirsjö A., Wiklund N.P. Enhanced formation of nitric oxide in bladder carcinoma in situ and in BCG-treated bladder cancer. Nitric Oxide 2006, 15:337-343.
17. Warpeha K.M., Xu W., Liu L., Charles I.G., Patterson C.C., Ah-Fat F., et al. Genotyping and functional analysis of a polymorphic (CCTTT)(n) repeat of NOS2A in diabetic retinopathy. FASEB J 1999, 13:1825-1832.
18. Gonzalez-Gay M.A., Llorca J., Sanchez E., Lopez-Nevot M.A., Amoli M.M., Garcia-Porrua C., et al. Inducible but not endothelial nitric oxide synthase polymorphism is associated with susceptibility to rheumatoid arthritis in northwest Spain. Rheumatology 2004, 43:1182-1185.
19. Tatemichi M., Sawa T., Gilibert I., Tazawa H., Katoh T., Ohshima H. Increased risk of intestinal type of gastric adenocarcinoma in Japanese women associated with long forms of CCTTT pentanucleotide repeat in the inducible nitric oxide synthase promoter. Cancer Lett 2005, 217:197-202.
20. Kaise M., Miwa J., Suzuki N., Mishiro S., Ohta Y., Yamasaki T., et al. Inducible nitric oxide synthase gene promoter polymorphism is associated with increased gastric mRNA expression of inducible nitric oxide synthase and increased risk of gastric carcinoma. Eur J Gastroenterol Hepatol 2007, 19:139-145.
21. Pomerleau C.S., Pomerleau O.F., Snedecor S.M., Mehringer A.M. Defining a never-smoker: results from the nonsmokers survey. Addict Behav 2004, 29:1149-1154.
22. DiClemente C.C., Delahanty J.C., Fiedler R.M. The journey to the end of smoking: a personal and population perspective. Am J Prev Med 2010, 38:418-428.
23. Couraud S., Zalcman G., Milleron B., Morin F., Souquet P.J. Lung cancer in never smokers: a review. Eur J Cancer 2012, 48:1299-1311.
24. Janković S., Radosavljević V. Risk factors for bladder cancer. Tumori 2007, 93:4-12.
25. Pelucchi C., Bosetti C., Negri E., Malvezzi M., La Vecchia C. Mechanisms of disease: the epidemiology of bladder cancer. Nat Clin Pract Urol 2006, 3:327-340.
26. Zeegers M.P., Goldbohm R.A., van den Brandt P.A. A prospective study on active and environmental tobacco smoking and bladder cancer risk (The Netherlands). Cancer Causes Control 2002, 13:83-90.
27. Samanic C., Kogevinas M., Dosemeci M., Malats N., Real F.X., Garcia-Closas M., et al. Smoking and bladder cancer in Spain: effects of tobacco type, timing, environmental tobacco smoke, and gender. Cancer Epidemiol Biomarkers Prev 2006, 15:1348-1354.
28. Kellen E., Zeegers M., Paulussen A., Vlietinck R., Vlem E.V., Veulemans H., et al. Does occupational exposure to PAHs, diesel and aromatic amines interact with smoking and metabolic genetic polymorphisms to increase the risk on bladder cancerα The Belgian case control study on bladder cancer risk. Cancer Lett 2007, 245:51-60.
29. Georgiadis P., Demopoulos N.A., Topinka J., Stephanou G., Stoikidou M., Bekyrou M., et al. Impact of phase I or phase II enzyme polymorphisms on lymphocyte DNA adducts in subjects exposed to urban air pollution and environmental tobacco smoke. Toxicol Lett 2004, 149:269-280.
30. Pandith A.A., Khan N.P., Shah Z.A., Shah A.M., Wani S.M., Siddiqi M.A. Association of bladder cancer risk with an NAD(P)H:quinone oxidoreductase polymorphism in an ethnic Kashmiri population. Biochem Genet 2011, 49:417-426.
31. Choi J.Y., Lee K.M., Cho S.H., Kim S.W., Choi H.Y., Lee S.Y., et al. CYP2E1 and NQO1 genotypes, smoking and bladder cancer. Pharmacogenetics 2003, 13:349-355.
32. Park S.J., Zhao H., Spitz M.R., Grossman H.B., Wu X. An association between NQO1 genetic polymorphism and risk of bladder cancer. Mutat Res 2003, 536:131-137.
33. Ohshima H., Bartsch H. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat Res 1994, 305:253-264.
34. Fransen K., Elander N., Soderkvist P. Nitric oxide synthase 2 (NOS2) promoter polymorphisms in colorectal cancer. Cancer Lett 2005, 225:99-103.
35. Liao L., Lim M.C., Chan S.W., Zhao J.J., Lee K.O. Nitric oxide synthase gene polymorphisms and nephropathy in Asians with type 2 diabetes. J Diabetes Complications 2006, 20:371-375.